PROSTVAC® and Ipilimumab Phase 1 Study Supports Rationale for Combining Two Immunotherapies for Prostate Cancer
KVISTGAARD, Denmark, February 23, 2012 - Bavarian
Nordic A/S (OMX: BAVA) announced today that a newly published study
suggests potential synergy of the Company's PROSTVAC®
investigational therapeutic cancer vaccine when used in combination
with ipilimumab, another immune therapy. Results of the Phase
1 dose escalation study were published in the journal The
Lancet Oncology. The scientific findings of this Phase 1
potentially provide proof of concept that the combination of an
immune checkpoint inhibitor with a therapeutic cancer vaccine is
feasible and might enhance the clinical efficacy of the combination
treatment. Several other NCI-funded combination studies with
PROSTVAC® are currently ongoing.
According to James L. Gulley, M.D., Ph.D., Director of the
Clinical Trials Group at the Laboratory of Tumor Immunology and
Biology at the National Cancer Institute (NCI), stated in the paper
that although the Phase 1 trial was small and non-randomized, the
median overall survival of 34.4 months for the 30 patients treated
raises the possibility that the combination ipilimumab and
PROSTVAC® might result in prolonged overall survival.
"In a randomized placebo-controlled Phase 2 study,
PROSTVAC® demonstrated an 8.5-month improvement in median
overall survival, in men with mCRPC. Based upon these encouraging
results, we recently initiated our pivotal global Phase 3 clinical
study PROSPECT," stated Anders Hedegaard, President & CEO
of Bavarian Nordic. "To further enhance the potential efficacy
of PROSTVAC®, we studied PROSTVAC® in combination with
ipilimumab and are encouraged by the observed safety and efficacy
profile of the immunotherapeutic combination."
Anders Hedegaard, President & CEO.
Phone: +45 23 20 30 64